BlackRock
INMB icon

BlackRock’s INmune Bio INMB Stock Holding History

BlackRock’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Sell
1,194,112
-17,988
-1% -$25.6K ﹤0.01% 4242
2025
Q4 		$1.89M Buy
1,212,100
+25,224
+2% +$45K ﹤0.01% 4129
2025
Q3 		$2.46M Buy
1,186,876
+14,435
+1% +$33K ﹤0.01% 4028
2025
Q2 		$2.71M Buy
1,172,441
+224,079
+24% +$1.64M ﹤0.01% 3980
2025
Q1 		$7.41M Sell
948,362
-41,196
-4% -$327K ﹤0.01% 3468
2024
Q4 		$4.62M Buy
989,558
+50,090
+5% +$261K ﹤0.01% 3760
2024
Q3 		$5.06M Buy
939,468
+126,573
+16% +$900K ﹤0.01% 3692
2024
Q2 		$7.17M Buy
812,895
+572,729
+238% +$5.65M ﹤0.01% 3554
2024
Q1 		$2.82M Sell
240,166
-17,763
-7% -$215K ﹤0.01% 3876
2023
Q4 		$2.9M Buy
257,929
+25,105
+11% +$210K ﹤0.01% 3898
2023
Q3 		$1.58M Sell
232,824
-6,809
-3% -$56.5K ﹤0.01% 4088
2023
Q2 		$2.18M Buy
239,633
+4,909
+2% +$39.4K ﹤0.01% 4020
2023
Q1 		$1.52M Sell
234,724
-601
-0.3% -$4.84K ﹤0.01% 4177
2022
Q4 		$1.49M Buy
235,325
+2,082
+0.9% +$14.8K ﹤0.01% 4256
2022
Q3 		$1.45M Sell
233,243
-877
-0.4% -$7.7K ﹤0.01% 4344
2022
Q2 		$2.07M Buy
234,120
+2,121
+0.9% +$15.8K ﹤0.01% 4241
2022
Q1 		$1.95M Sell
231,999
-1,266
-0.5% -$11.4K ﹤0.01% 4407
2021
Q4 		$2.38M Buy
233,265
+86,836
+59% +$1.29M ﹤0.01% 4338
2021
Q3 		$2.84M Sell
146,429
-37,577
-20% -$726K ﹤0.01% 4170
2021
Q2 		$3.23M Sell
184,006
-35,724
-16% -$481K ﹤0.01% 4065
2021
Q1 		$2.61M Buy
219,730
+198,487
+934% +$3.57M ﹤0.01% 4207
2020
Q4 		$366K Buy
21,243
+2,854
+16% +$26.9K ﹤0.01% 4391
2020
Q3 		$190K Sell
18,389
-413
-2% -$4.2K ﹤0.01% 4419
2020
Q2 		$98K Buy
18,802
+3,050
+19% +$15.4K ﹤0.01% 4492
2020
Q1 		$52K Buy
15,752
+9,200
+140% +$41.6K ﹤0.01% 4463
2019
Q4 		$38K Buy
6,552
+2,597
+66% +$12.5K ﹤0.01% 4572
2019
Q3 		$24K Buy
3,955
+907
+30% +$6.71K ﹤0.01% 4626
2019
Q2 		$29K Buy
3,048
+2,864
+1,557% +$29K ﹤0.01% 4640
2019
Q1 		$1K Buy
+184
New +$1.42K ﹤0.01% 4875

Other funds holding INMB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

BlackRock's INMB Position: Q1 2026 in Review

BlackRock reduced its INmune Bio (INMB) stake by 1.5% in Q1 2026, selling an estimated $25.6K and leaving 1,194,112 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4242.

BlackRock first reported a position in INMB in Q1 2019 and has held it in 29 quarters since. The position peaked at $7.41M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • BlackRock held 1,194,112 shares of INmune Bio worth $1.35M as of Q1 2026.
  • BlackRock sold 17,988 INmune Bio shares in Q1 2026, an estimated $25.6K.
  • INmune Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4242 holding.
  • BlackRock first reported a position in INmune Bio in Q1 2019 and has held it in 29 quarters since.
  • BlackRock's INmune Bio position peaked at $7.41M in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.